KemPharm to Report Second Quarter 2020 Financial Results
August 04 2020 - 7:30AM
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs,
today announced that the Company will host a conference call and
live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m.
ET, to discuss its corporate and financial results for the second
quarter 2020.
Conference Call Information: Interested
participants and investors may access the conference call by
dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 5176398
An audio webcast with slide presentation will be
accessible via the Investor Relations section of the Company’s
website, http://investors.kempharm.com/. An archive of the
webcast and presentation will be available for 90 days beginning at
approximately 5:30 p.m. ET, on August 12, 2020.
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LATTM
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LATTM technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, and stimulant use disorder. KemPharm’s co-lead
clinical development candidates for the treatment of ADHD, KP415
and KP484, are both based on a prodrug of d-methylphenidate, but
have differing duration/effect profiles. In addition, KemPharm has
received FDA approval for APADAZ®, an immediate-release combination
product containing benzhydrocodone, a prodrug of hydrocodone, and
acetaminophen. For more information on KemPharm and its pipeline of
prodrug product candidates visit www.kempharm.com or connect with
us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts: |
Jason Rando / Maureen McEnroe Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664 jrando@tiberend.com mmcenroe@tiberend.com |
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024